Northeast Financial Consultants Inc Makes New Investment in Gelesis Holdings, Inc. (NYSE:GLS)
Northeast Financial Consultants Inc Makes New Investment in Gelesis Holdings, Inc. (NYSE:GLS)
Northeast Financial Consultants Inc acquired a new stake in shares of Gelesis Holdings, Inc. (NYSE:GLS – Get Rating) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 35,000 shares of the company's stock, valued at approximately $158,000. Northeast Financial Consultants Inc owned about 0.10% of Gelesis at the end of the most recent reporting period.
東北金融顧問公司在向美國證券交易委員會（SEC）提交的最新文件中稱，該公司在第一季度收購了Gelesis Holdings, Inc.（紐約證券交易所代碼：GLS — 獲取評級）的新股份。該公司收購了該公司35,000股股票，價值約爲15.8萬美元。在最近的報告期末，東北金融顧問公司擁有Gelesis約0.10％的股份。
Gelesis Trading Up 2.5 %
蓋萊西斯交易量上漲2.5％
Gelesis stock opened at $1.21 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.62 and a debt-to-equity ratio of 5.89. Gelesis Holdings, Inc. has a 1 year low of $1.01 and a 1 year high of $12.23. The firm's 50 day moving average price is $1.44 and its 200-day moving average price is $3.23.
Gelesis股票週四開盤價爲1.21美元。該公司的流動比率爲0.89，速動比率爲0.62，債務與權益比率爲5.89。Gelesis Holdings, Inc.的1年低點爲1.01美元，爲1年高點12.23美元。該公司的50天移動平均價格爲1.44美元，其200天移動平均線價格爲3.23美元。
Insider Activity
內幕活動
In related news, Director Raju S. Kucherlapati acquired 24,625 shares of Gelesis stock in a transaction dated Wednesday, June 15th. The shares were purchased at an average price of $1.95 per share, for a total transaction of $48,018.75. Following the completion of the transaction, the director now directly owns 90,264 shares in the company, valued at approximately $176,014.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
在相關新聞中，董事拉朱·庫切拉帕蒂在6月15日星期三的交易中收購了Gelesis的24,625股股票。這些股票以每股1.95美元的平均價格購買，總交易額爲48,018.75美元。交易完成後，該董事現在直接擁有該公司的90,264股股票，價值約176,014.80美元。該交易已在向美國證券交易委員會提交的文件中披露，可以通過此超鏈接訪問該文件。
Gelesis Profile
蓋萊西斯簡介
Gelesis Holdings Inc, a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.
Gelesis Holdings Inc是一家處於商業階段的生物療法公司，正在開發一種用於治療肥胖和胃腸道相關慢性病的起因的生物仿生物。該公司還提供 PLENITY，這是一種用於體重管理的口服、非興奮劑和非全身性輔助藥物。此外，它還提供針對肥胖和超重的產品，以及非酒精性脂肪肝疾病/非酒精性脂肪性肝炎、2 型糖尿病和功能性便祕的 GS500 的潛在療法在研產品線。
Featured Stories
精選故事
- Get a free copy of the StockNews.com research report on Gelesis (GLS)
- How will the chip ban affect Nvidia's stock?
- Is Best Buy A Sneaky Buy for Q4?
- Does The Bed Bath and Beyond Stock Rally Still Have Legs?
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- 免費獲取 StockNews.com 關於 Gelesis（GLS）的研究報告的副本
- 芯片禁令將如何影響英偉達的股票？
- 百思買是第四季度的偷偷買嗎？
- Bed Bath and Beyond 股票反彈還能站穩腳跟嗎？
- 阿里巴巴和百度能否在退市恐懼消失的情況下最終反彈？
- 3只可能在你的關注名單上佔有一席之地的材料股
Receive News & Ratings for Gelesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelesis and related companies with MarketBeat.com's FREE daily email newsletter.
接收《蓋萊西斯日報》的新聞和收視率 -在下面輸入您的電子郵件地址，以通過Marketbeat.com的免費每日電子郵件時事通訊接收有關Gelesis及相關公司最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。